Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Douxfils

Showing results (11-20 of 221) with videos related to

Pageof 23
Sort By:
The Journal of Infection|May 21, 2023
Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infectionJulien Favresse, Julien Cabo, Jonathan Douxfils
Seminars in Thrombosis and Hemostasis|October 20, 2020
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the RiskJonathan Douxfils, Laure Morimont, Céline Bouvy
Microorganisms|September 28, 2021
Reply to Schulte-Pelkum, J. Comment on "Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> 2021, <i>9</i>, 556"Julien Favresse, Constant Gillot, Jonathan Douxfils
Expert Opinion on Pharmacotherapy|September 26, 2024
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balanceJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Expert Opinion on Drug Safety|May 22, 2015
Dose tailoring of dabigatran etexilate: obvious or excessive?Jonathan Douxfils, François Mullier, Jean-Michel Dogné
Thrombosis Research|August 18, 2020
Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled "Estrogen and thrombosis: A bench to bedside review" (Thrombosis Research 192 (2020) 40-51)Laure Morimont, Jean-Michel Dogné, Jonathan Douxfils
Lancet (London, England)|October 21, 2023
Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetantJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Menopause (New York, N.Y.)|July 26, 2024
Letter to the EditorJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 17, 2024
Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trialsJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
JAMA Oncology|June 10, 2016
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-ReplyJonathan Douxfils, Hélène Haguet, Jean-Michel Dogné
Pageof 23

Showing results (11-20 of 221) with videos related to

Sort By:
Pageof 23
The Journal of Infection|May 21, 2023
Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infectionJulien Favresse, Julien Cabo, Jonathan Douxfils
Seminars in Thrombosis and Hemostasis|October 20, 2020
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the RiskJonathan Douxfils, Laure Morimont, Céline Bouvy
Microorganisms|September 28, 2021
Reply to Schulte-Pelkum, J. Comment on "Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> 2021, <i>9</i>, 556"Julien Favresse, Constant Gillot, Jonathan Douxfils
Expert Opinion on Pharmacotherapy|September 26, 2024
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balanceJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Expert Opinion on Drug Safety|May 22, 2015
Dose tailoring of dabigatran etexilate: obvious or excessive?Jonathan Douxfils, François Mullier, Jean-Michel Dogné
Thrombosis Research|August 18, 2020
Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled "Estrogen and thrombosis: A bench to bedside review" (Thrombosis Research 192 (2020) 40-51)Laure Morimont, Jean-Michel Dogné, Jonathan Douxfils
Lancet (London, England)|October 21, 2023
Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetantJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
Menopause (New York, N.Y.)|July 26, 2024
Letter to the EditorJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 17, 2024
Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trialsJonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné
JAMA Oncology|June 10, 2016
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-ReplyJonathan Douxfils, Hélène Haguet, Jean-Michel Dogné
Pageof 23